v3.26.1
Collaborative Arrangements and Licensing Agreements - Roche (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
USD ($)
Agreement
Mar. 31, 2026
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
Agreement
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Roche [Member]            
Collaborative Arrangements and Licensing Agreements [Abstract]            
Number of collaboration agreements (in Agreement) | Agreement 2     2    
Revenue $ 0   $ 2,403 $ 50,000 $ 4,368  
Deferred contract revenue 0     0   $ 0
Roche [Member] | Minimum [Member]            
Collaborative Arrangements and Licensing Agreements [Abstract]            
Cumulative payments received $ 405,000     $ 405,000    
Sefaxersen for Complement-Mediated Diseases [Member]            
Collaborative Arrangements and Licensing Agreements [Abstract]            
Number of collaboration agreements (in Agreement) | Agreement 1     1    
RNA-targeted Programs for AD and HD [Member]            
Collaborative Arrangements and Licensing Agreements [Abstract]            
Number of collaboration agreements (in Agreement) | Agreement 1     1    
Revenue   $ 50,000        
Next payment to be achieved $ 10,000     $ 10,000